Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | APLNR | P35414 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23748309 | 1.00 | — | — | |
| SCHEMBL3112379 | 1.00 | — | — | |
| SCHEMBL8304534 | 1.00 | — | — | |
| SCHEMBL350838 | 1.00 | EPHX2 (0.52) | EPHX2APLNRNR1H2ALDH1A1BRD4 | |
| SCHEMBL350839 | 1.00 | EPHX2 (0.52) | EPHX2APLNRNR1H2ALDH1A1BRD4 | |
| Ammonia Solution, Strong SCHEMBL8050388 | 0.96 | — | — | |
| SCHEMBL19663557 | 0.86 | EPHX2 (0.44) | EPHX2APLNR | |
| SCHEMBL18849923 | 0.86 | EPHX2 (0.44) | EPHX2APLNR | |
| SCHEMBL52490 | 0.84 | — | — | |
| SCHEMBL23136777 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317148-A1 | Systems and Methods for Mechanosynthesis | CBN NANO TECHNOLOGIES INC. (CA) | 2021-10-14 | — | — | US | disclosed |
| US-10197597-B2 | Build sequences for mechanosynthesis | CBN NANO TECHNOLOGIES INC. (CA) | 2019-02-05 | — | — | US | disclosed |
| US-20180044669-A1 | COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF | IDERA PHARMACEUTICALS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20180044669-A1 | COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF | IDERA PHARMACEUTICALS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-9828601-B2 | Compositions for inhibiting checkpoint gene expression and uses thereof | IDERA PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828601-B2 | Compositions for inhibiting checkpoint gene expression and uses thereof | IDERA PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044669-A1 | COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF | CD274, PDCD1LG2, PDCD1 | EPHX2 2595/4885APLNR 2180/4885NR1H2 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.